ANG Lifesciences India Limited (BOM:540694)
India · Delayed Price · Currency is INR 29.85
-1.57 (-5.00%)
At close: Aug 17, 2026
ANG Lifesciences India Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Operating Revenue | - | 928.47 | 1,461 | 2,199 | 3,543 | 1,544 |
Other Revenue | - | - | - | - | - | -0 |
| - | 928.47 | 1,461 | 2,199 | 3,543 | 1,544 | |
Revenue Growth | - | -36.45% | -33.55% | -37.94% | 129.50% | 21.72% |
Cost of Revenue | - | 596.23 | 951.13 | 1,506 | 2,280 | 1,040 |
Gross Profit | - | 332.24 | 509.97 | 693.01 | 1,263 | 504.18 |
Selling, General & Admin | - | 178.11 | 196.85 | 243.32 | 214.77 | 139.98 |
Other Operating Expenses | - | 159.49 | 215.62 | 221.53 | 371.08 | 224.47 |
Operating Expenses | - | 405.2 | 496.19 | 558.38 | 644.6 | 377.62 |
Operating Income | - | -72.97 | 13.78 | 134.63 | 618.6 | 126.57 |
Interest Expense | - | -88.8 | -103.22 | -111.93 | -82.8 | -30.73 |
Interest & Investment Income | - | 2.26 | 5.28 | 6.46 | 2.9 | 2.03 |
Currency Exchange Gain (Loss) | - | - | -0.98 | -4.51 | -1.71 | - |
Other Non Operating Income (Expenses) | - | 2.47 | -6.35 | -6.85 | -0.93 | 3.53 |
EBT Excluding Unusual Items | - | -157.04 | -91.49 | 17.81 | 536.07 | 101.39 |
Gain (Loss) on Sale of Assets | - | - | 1.71 | 8.44 | -1.06 | - |
Other Unusual Items | - | - | -17.35 | - | - | - |
Pretax Income | - | -157.04 | -107.14 | 26.25 | 535.01 | 101.39 |
Income Tax Expense | - | -32.9 | -5.71 | 28.87 | 131.84 | 31.11 |
Net Income | - | -124.13 | -101.43 | -2.62 | 403.17 | 70.28 |
Net Income to Common | - | -124.13 | -101.43 | -2.62 | 403.17 | 70.28 |
Net Income Growth | - | - | - | - | 473.69% | 15.29% |
Shares Outstanding (Basic) | 13 | 13 | 13 | 13 | 13 | 13 |
Shares Outstanding (Diluted) | 13 | 13 | 13 | 13 | 13 | 13 |
Shares Change | -0.82% | - | 0.51% | 0.26% | - | - |
EPS (Basic) | - | -9.51 | -7.77 | -0.20 | 31.11 | 5.42 |
EPS (Diluted) | - | -9.51 | -7.77 | -0.20 | 31.11 | 5.42 |
EPS Growth | - | - | - | - | 473.69% | 15.29% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Free Cash Flow | - | -40.07 | -150.63 | 159.33 | -166.28 | 49 |
Free Cash Flow Per Share | - | -3.07 | -11.54 | 12.26 | -12.83 | 3.78 |
Dividend Per Share | - | - | - | - | 0.800 | - |
Dividend Growth | - | - | - | - | - | - |
Gross Margin | - | 35.78% | 34.90% | 31.52% | 35.65% | 32.66% |
Operating Margin | - | -7.86% | 0.94% | 6.12% | 17.46% | 8.20% |
Profit Margin | - | -13.37% | -6.94% | -0.12% | 11.38% | 4.55% |
Free Cash Flow Margin | - | -4.32% | -10.31% | 7.25% | -4.69% | 3.17% |
EBITDA | - | -19.06 | 88.95 | 225.34 | 677.17 | 139.73 |
EBITDA Margin | - | -2.05% | 6.09% | 10.25% | 19.11% | 9.05% |
D&A For EBITDA | - | 53.91 | 75.17 | 90.71 | 58.58 | 13.17 |
EBIT | - | -72.97 | 13.78 | 134.63 | 618.6 | 126.57 |
EBIT Margin | - | -7.86% | 0.94% | 6.12% | 17.46% | 8.20% |
Effective Tax Rate | - | - | - | 109.99% | 24.64% | 30.69% |
Revenue as Reported | - | 948.66 | 1,468 | 2,296 | 3,552 | 1,549 |
Advertising Expenses | - | - | 0.08 | - | - | 0.73 |